Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials

Acta Oncologica

Volumn 50, Issue 4, 2011, Pages 582-588

  Jiang, Jingwei ^a,b   Huang, Lizhen ^c   Liang, Xiaohua ^a,b,d   Zhou, Xinli ^a,b   Huang, Ruofan ^a,b   Chu, Zhaohui ^a,b   Zhan, Qiong ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d NONE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GEFITINIB;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; FATIGUE; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; QUALITY OF LIFE; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 79955587730     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.546368     Document Type: Article

References (21)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94: 153-6. (Pubitemid 32911406)
2. Novello S, Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease. Oncology (Williston Park) 2003;17:357-64.
3. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;7:6251-66.
4. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
5. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al, Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall- cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103. (Pubitemid 30324363)
6. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-46. (Pubitemid 46621858)
7. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager Jr D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003;290:2149-58. (Pubitemid 37432975)
8. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, Pawel J von, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37. (Pubitemid 41540110)
9. Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K. Phase II, open-label, randomized study (SIGN) of singleagent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 2006;17:401-9. (Pubitemid 44309982)
10. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated nonsmall- cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008;372:1809-18.
11. Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008; 26:4244-52.
12. Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, et al. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010;16:1307-14.
13. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghanet DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12. (Pubitemid 26120810)
14. D eeks J, Altman D, Bradburn M. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In Egger M, Smith GR, Altman DG, editors. Systematic reviews in health care: Meta-analysis in context. 2 nd ed. London, UK: BMJ Books; 2001. pp 285-312.
15. Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervaiset R, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744-52.
16. Sekine I, Ichinose Y, Nishiwaki Y, Yamamoto N, Tsuboi M, Nakagawa K, et al. Quality of life and disease-related symptoms in previously treated Japanese patients with nonsmall- cell lung cancer: Results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol 2009;20:1483-8.
17. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50: 1088-101.
18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-34. (Pubitemid 27387172)
19. Tsujino K, Kawaguchi T, Kubo A, Aono N, Nakao K, Koh Y, et al. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol 2009;4:994-1001.
20. Shepherd FA, Douillard J, Fukuoka M, Saijo N, Kim S, Cufer T, et al. Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials. J Clin Oncol 2009;27:15s (Suppl; abstr 8011).
21. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-42. (Pubitemid 46631407)